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We have recently shown that interferon regulatory factor 7 (IRF7) is activated by Epstein-Barr virus latent
membrane protein 1 (LMP1), a member of the tumor necrosis factor receptor (TNFR) superfamily, through
receptor-interacting protein-dependent K63-linked ubiquitination (L. E. Huye, S. Ning, M. Kelliher, and J. S.
Pagano, Mol. Cell. Biol. 27:2910–2918, 2007). In this study, with the use of small interfering RNA and
TNFR-associated factor 6 (TRAF6) knockout cells, we first show that TRAF6 and its E3 ligase activity are
required for LMP1-stimulated IRF7 ubiquitination. In Raji cells which are latently infected and express high
levels of LMP1 and IRF7 endogenously, expression of a TRAF6 small hairpin RNA construct reduces endog-
enous ubiquitination and endogenous activity of IRF7. In TRAF6/ mouse embryonic fibroblasts, reconsti-
tution with TRAF6 expression, but not with TRAF6(C70A), which lacks the E3 ligase activity, recovers LMP1’s
ability to stimulate K63-linked ubiquitination of IRF7. Further, we identify IRF7 as a substrate for TRAF6 E3
ligase and show that IRF7 is ubiquitinated by TRAF6 at multiple sites both in vitro and in vivo. Most
important, we determine that the last three C-terminal lysine sites (positions 444, 446, and 452) of human IRF7
variant A are essential for activation of IRF7; these are the first such sites identified. A ubiquitination-deficient
mutant of IRF7 with these sites mutated to arginines completely loses transactivational ability in response not
only to LMP1 but also to the IRF7 kinase IB kinase . In addition, we find that K63-linked ubiquitination of
IRF7 occurs independently of its C-terminal functional phosphorylation sites. These data support our hypoth-
esis that regulatory ubiquitination of IRF7 is a prerequisite for its phosphorylation. This is the first evidence
to imply that ubiquitination is required for phosphorylation and activation of a transcription factor.
Intracellular signaling initiated by latent membrane protein
1 (LMP1), the principal oncoprotein of the human gammaher-
pesvirus Epstein-Barr virus (EBV), is of interest not only for
viral oncogenesis but also for the reason that LMP1 shares
early steps in pathways used by CD40, interleukin-1 (IL-1)
receptor–Toll-like receptor (TLR), and tumor necrosis factor
receptor (TNFR) for activation of NFB (reviewed in refer-
ences 16 and 35). As a member of the TNFR superfamily,
LMP1 recruits TNFR-associated death domain protein, TNFR-
interacting protein (RIP), and several TNFR-associated factors
(TRAFs). Unlike CD40 and receptor activator of NF-B
(RANK), which contain TRAF6-binding sites, LMP1 does not
have a consensus TRAF6-binding sequence but associates with
TRAF6 indirectly (reviewed in references 8, 16, 35, 51, and 61).
Ubiquitination through K48-polyubiquitin linkage is well
known as a process whereby proteins are targeted for protea-
somal degradation. Recently, proteasome-independent func-
tions for ubiquitination through K63 polyubiquitin or mono-
ubiquitin linkages have been identified, and the importance of
these ubiquitination events in a variety of cellular processes,
including receptor internalization, vesicle trafficking, DNA re-
pair, stress responses, and protein kinase activation, is becom-
ing increasingly recognized (reviewed in references 3, 15, 32,
42, and 52). Although TRAF6 is the only TRAF family mem-
ber which is essential for signaling from both the TNFR su-
perfamily and the IL-1 receptor–TLR superfamily, which con-
trol both innate and adaptive immune responses (reviewed in
references 7, 11, 28, 55, and 61), the mechanisms of TRAF6
action in these physiological processes have been elusive until
recent findings that unveiled its E3 ligase activity for K63-
linked ubiquitination in the activation of IB kinase (IKK) for
NFB activation (14, 58). Besides TRAF6, TRAF2, TRAF7,
TRAF3, and probably TRAF5 have also been shown to func-
tion as E3 ubiquitin (Ub) ligases. TRAF2, TRAF3 (31),
TRAF6, and probably TRAF5 and TRAF7 (6) can act for
K63-linked ubiquitination.
The interferon (IFN) regulatory factor (IRF) family has a
variety of functions. Besides regulation of expression of IFNs,
IRFs also play roles in oncogenesis (reviewed in references 53
and 54); in regulation of differentiation of hematopoietic cells,
the cell cycle, and apoptosis (54); and in regulation of many
autoimmune diseases, such as systemic lupus erythematosus,
psoriasis, and type I diabetes (2, 43). Recognition of the cen-
trality of IRF7 (66) in host immune defenses is highlighted by
recent discoveries that identify IRF7 as the master regulator of
all IFN-I-dependent immune responses (24) and activation of
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IRF7 triggered by intracellular TLRs and RIG-I-like receptors
(reviewed in references 12, 21, 29, 55, 63, and 64). How IRF7
is activated is therefore of central importance, and activation
of this protein by phosphorylation has been studied for some
years. In recent years, TRAF6 and TRAF3 have been shown to
play critical roles in TLR signaling for activation of IRF3/7
(reviewed in references 22 and 55). Further, TRAF6 (30)- and
TRAF3 (31)-mediated ubiquitination has been shown to be
involved in this process.
Recently, we have demonstrated that K63-linked ubiquitin-
ation of both IRF7 and RIP promotes the interaction of these
two proteins and causes functional activation of IRF7 (27).
That TRAF6 mediates ubiquitination of IRF7 by LMP1 was
suggested by observations from promoter-reporter assays with
a TRAF6 dominant-negative mutant but remained to be es-
tablished (27). Moreover, the interdependence between ubiq-
uitination and phosphorylation, if any, has been unexplored.
Here, we prove that TRAF6 is in fact required for LMP1-
stimulated transcriptional activity of IRF7 by acting as an E3
ligase responsible for regulatory ubiquitination of IRF7. Fur-
thermore, we identify three key lysine sites which are critical
for IRF7 activation in response to LMP1 and IKKε, implying
that ubiquitination on these sites is a prelude to phosphoryla-
tion of IRF7.
MATERIALS AND METHODS
Cell lines and antibodies. Raji is an EBV-infected human Burkitt’s lymphoma
B-cell line with type III latency. 293 and 293T cells were derived from human
kidney epithelial cells. TRAF6/ and TRAF6/ mouse embryonic fibroblasts
(MEFs) were gifts from Tak Mak (39). Raji cells were maintained in RPMI 1640
medium supplemented with 10% fetal bovine serum plus antibiotics, and 293
cells and MEFs were maintained in Dulbecco’s modified Eagle’s medium sup-
plemented with 10% fetal bovine serum plus antibiotics.
Monoclonal TRAF6, Myc (5E10), Ub, hemagglutinin (HA), and His antibod-
ies and polyclonal or monoclonal IRF7 and Ubc13 antibodies were purchased
from Santa Cruz. Monoclonal Flag (M2) and tubulin antibodies were purchased
from Sigma.
Constructs. pcDNA3.1-TRAF6 was a gift from Arnd Kieser (47). HA-Ub and
HA-K63Ub were gifts from David Boone and Averil Ma (5). IFN-4 promoter–
Luc (IFN-4p–Luc), Flag-IRF7, and its mutant Flag-IRF7(477A/479A) were
gifts from Rongtuan Lin and John Hiscott (37). pcDNA3-LMP1 and Flag-LMP1
were kindly provided by Nancy Raab-Traub (41). The Renilla (pRL-TK) expres-
sion construct was purchased from Promega. All other constructs and mutants
were made by subcloning or site-directed mutagenesis (Stratagene) and verified
by sequencing.
RNA interference. The four 19-nucleotide oligonucleotides for small interfer-
ing RNA (siRNA) targeted to human Ubc13 have been described previously (68)
and were synthesized (Invitrogen). The oligonucleotides of small interfering
TRAF6 targeting human TRAF6 (GenBank accession numbers NM_004620 and
NM_145803) were purchased from Dharmacon; the sequences are GGAGAA
ACCUGUUGUGAUUUU (sense) and AAUCACAACAGGUUUCUCCUU
(antisense). The control siRNA, a scrambled sequence without specific targeted
degradation of any known cellular mRNA, was purchased from Santa Cruz.
These siRNAs were transfected into 293 cells in 12-well plates with the use of
Lipofectamine 2000 according to the manufacturer’s instructions.
Generation of stable TRAF shRNA (shTRAF6)-expressing Raji cell lines. The
two complementary oligonucleotides for generating small hairpin RNA
(shRNA) targeting TRAF6 are as follows: sense, 5-gatccccCCACGAAGAGA
TAATGGATttcaagagaATCCATTATCTCTTCGTGGtttttggaaa-3; and anti-
sense, 5-tcgatttccaaaaaCCACGAAGAGATAATGGATtctcttgaaATCCATTA
TCTCTTCGTGGggg-3. For the negative control, the sequence targeting
TRAF6 was scrambled to 5-GCAAGCGAATCGATAAGTA-3, which does
not target any human gene. These sequences were synthesized, annealed, and
inserted at the BglII/XhoI sites of the pSuper.Retro/Puro vector driven by the
human H1 gene promoter (OligoEngine Inc.). Retroviral production and infec-
tion of Raji cells were performed as described previously (27). Stable transfec-
tants were selected by culturing for 2 weeks in the presence of 0.5 g/ml puro-
mycin (Mediatech Inc., Manassas, VA).
Protein expression and purification. For FLAG elution, 293T cells were trans-
fected with the Flag-IRF7 construct. After 48 h, cells were collected in phos-
phate-buffered saline solution and Dounce homogenized in 100 l hypotonic
lysis buffer (10 mM NaCl, 1.5 mM MgCl2, 10 mM Tris, pH 7.5, and complete
protease inhibitor cocktail [Roche]). Supernatant fluids were denatured at 95°C
for 5 min with addition of sodium dodecyl sulfate (SDS) to give a final concen-
tration of 1% and then diluted 10-fold with dilution buffer (50 mM Tris-HCl, pH
7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, and complete protease
inhibitors) and immunoprecipitated with anti-FLAG affinity gel (Sigma) over-
night (59). Samples were eluted with 300 g/ml FLAG peptide (Sigma) accord-
ing to the manufacturer’s instructions.
Protein expression and purification from Escherichia coli were performed as
described previously for His-tagged proteins (17) or for glutathione S-transferase
(GST)-tagged proteins (34).
In vitro and in vivo ubiquitination assays. In vitro ubiquitination assays using
His-TRAF6 and Flag-IRF7 were performed as described previously (59). For
GST-tagged proteins, purified GST-TRAF6 and GST-IRF7-Flag or their mu-
tants were incubated for 3 h at 37°C in 20 l of a reaction buffer (20 mM HEPES
[pH 7.4], 10 mM MgCl2, 1 mM dithiothreitol [DTT], 59 M Ub, 50 nM E1, 850
nM of Ubc13-UeV1a, 1 mM ATP, 30 M creatine phosphate, and 1 U of
creatine kinase). After incubation, the beads were washed five times in buffer A
(20 mM Tris, pH 7.4, 250 mM NaCl, 1 mM DTT, 1 mM sodium orthovanadate,
2 mM EDTA, 1% Triton X-100) and two times in low-salt buffer (20 mM Tris,
pH 7.4, 25 mM NaCl, 1 mM DTT). Beads were then resuspended in 1% SDS (in
water) and boiled for 10 min. Dissociated proteins were diluted 50 l twice, each
with 600 l buffer A, and supernatant fluid was precleared with protein A/G
beads (Santa Cruz) for 1 h and immunoprecipitated overnight with 1 g anti-
Flag M2, after which protein A/G beads were added for an additional 1 h. Beads
were washed four times with buffer A and two times with low-salt buffer before
Western blotting.
For the in vivo ubiquitination assay, 293 cells in six-well plates were transfected
with 0.5 g HA-Ub, 0.6 g pCR3-FlagTRAF6, and 1.0 g pcDNA3-IRF7 by
using CalPho transfection reagent (Clontech). Cells were harvested after 36 h
and lysed in 200 l of buffer A with the addition of 10 mM N-ethylmaleimide for
30 min on ice. Three hundred micrograms of total proteins was used for immu-
noprecipitation (IP), and 30 g was used for input controls. Lysates for IP were
diluted with 1.2 ml of buffer A, and IP was performed with 2 g anti-IRF7 and
protein A/G-Sepharose beads (Santa Cruz) for 4 h. Beads were washed four
times in buffer A and two times with low-salt buffer denatured in 50 l of 1%
SDS. A second IP was performed as described above with 1 g anti-IRF7 and
protein A/G beads overnight. Beads were washed four times with buffer A and
two times with low-salt buffer before Western blotting with anti-HA.
RNA extraction and RT-PCR. RNA was extracted with the use of a Qiagen
mini-RNA preparation kit, following the manufacturer’s instructions. Reverse
transcription (RT)-PCR was performed with the use of an RT-PCR system
(Promega). cDNA products were diluted five times. Five microliters of diluted
cDNA was used for IFN-stimulated gene 56 (ISG56) and IRF7 and 2 l for actin.
The primers used for PCR are as follows: for IRF7, CGCGGCACTAACGAC
AGGCGAG (forward) and GCTGCCGTGCCCGGAATTCCAC) (reverse); for
ISG56, CCAGCGCTGGGTATGCGATCTCTGCC (forward) and GGGCCCG
CTCATAGTACTCCAGGGC (reverse); and for actin, ACAATGAGCTGCTG
GTGGCT (forward) and GATGGGCACAGTGTGGGTGA (reverse). PCR
was performed in the linear range (30 cycles) at an annealing temperature
of 60°C.
Transfection, reconstitution, IP, and immunoblotting. 293 cells were trans-
fected with Effectene reagent (Invitrogen), and MEFs were transfected with an
Amaxa Nucleofector II MEF kit, following the manufacturer’s instructions. Re-
constitutions of TRAF6 knockout cells with Myc-TRAF6 or Myc-TRAF6(C70A)
were completed by selection with 4 mg/ml G418 for 2 weeks after transfection.
For IP, transfected 293 cells in 60-mm dishes or MEFs from three combined
transfections were collected 48 h after transfection. Except for those shown in
Fig. 2B, cell lysates were denatured in 1% SDS at 95°C for 10 min to dissociate
any noncovalently bound proteins and diluted 10 before IP, or a second IP was
performed with immunoprecipitates denatured in 1% SDS at 95°C for 10 min (4,
33, 59). Proteins were separated by SDS-polyacrylamide gel electrophoresis and
transferred to nitrocellulose membranes, followed by immunoblotting with the
indicated antibodies, and signals were detected with an enhanced chemilumines-
cence kit, following the manufacturer’s protocol (Amersham Pharmacia Bio-
tech).
Luciferase assay and data analysis. Cells were transfected with the indicated
expression plasmids, together with IFN-4p–Luc. Renilla was cotransfected as an
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internal transfection control. Empty vector was used to equalize the total amount
of DNA in all transfections. Cells were collected 24 h after transfection. Lucif-
erase activity was measured with equal amounts (20% of the total for each
sample) of protein lysates in an Lmax luminometer (Molecular Devices Corp.)
with the use of a dual luciferase assay kit (Promega). The results shown are
averages  standard errors from duplicates for each sample. At least three
consistent results were obtained from independent experiments, and represen-
tative results are shown. The value for the ability of the vector controls to activate
IFN-4p–Luc was set to 1.
RESULTS
TRAF6 activates IRF7 and enhances LMP1-promoted IRF7
activity. We propose that TRAF6 is an E3 ligase for IRF7
K63-linked ubiquitination for the following reasons: first,
TRAF6 is an E3 Ub ligase for K63-linked polyubiquitination
(14); second, TRAF6 is involved in LMP1 signaling (47, 57);
third, TRAF6 interacts with IRF7 and activates it in response
to TLR signaling (30); and last, TRAF6 can also associate with
RIP, which is required for LMP1 signaling to IRF7 (27),
through the adaptor protein p62 (46). However, evidence for
this proposal is not complete.
Here, we first tested the effect of TRAF6 on the transcrip-
tional activity of IRF7. Luciferase assay results show that IRF7
(Fig. 1A) is activated by TRAF6, but not by TRAF2, in a
dose-dependent manner. Further, TRAF6 enhances LMP1-
promoted IRF7 transcriptional activity (Fig. 1B). The results
suggest that TRAF6 in involved in LMP1 activation of IRF7.
LMP1 activates TRAF6 and enhances its interaction with
IRF7. Next, we inquired whether LMP1 could activate TRAF6
FIG. 1. TRAF6 activates IRF7 and enhances LMP1-stimulated IRF7 activity. 293 cells in 24-well plates were transfected with 10 ng IRF7,
increasing amounts of TRAF6 or TRAF2 (, 20 ng; , 50 ng; and , 100 ng) (A) or 20 ng TRAF6 and 50 ng LMP1 (B), 25 ng IFN-4p–Luc,
and 10 ng Renilla. Luciferase activity was measured 24 h after transfection. (A) TRAF6 but not TRAF2 activates IRF7 in a dose-dependent
manner. (B) TRAF6 increases LMP1-stimulated IRF7 activity.
FIG. 2. LMP1 activates TRAF6 and enhances its association with IRF7. (A) LMP1 activates TRAF6. Endogenous TRAF6 is activated in the
presence of LMP1 and HA-K63Ub and therefore autoubiquitinated (lanes 1 and 2). 293 cells in 60-mm dishes were transfected with 0.2 g
Flag-LMP1 and 0.5 g HA-K63Ub. Transfected cells were collected for IP after 48 h. IB, immunoblotting; TRAF6, anti-TRAF6. (B) LMP1
enhances interaction between IRF7 and TRAF6. 293 cells in 60-mm dishes were transfected with 0.2 g pcDNA3-LMP1, 0.5 g Flag-TRAF6, 0.5
g Myc-IRF7, and 0.5 g HA-K63Ub. Cells were collected for IP after 48 h.
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and enhance its interaction with IRF7. TRAF6 E3 ligase is
activated after dimerization or oligomerization and targets
itself as one of the substrates for K63-linked ubiquitination
(58). 293 cells were transfected with constructs as indicated
(Fig. 2). Cells were collected after 48 h, and lysates were
denatured (Fig. 2A) or not denatured (Fig. 2B) before IP.
Western blotting was performed with the antibodies as in-
dicated. Figure 2A shows that in the absence of exogenous
TRAF6, ubiquitination of endogenous TRAF6 is not detect-
able under our experimental conditions even with transient
expression of HA-K63Ub (Fig. 2A, lane 1), but significant
ubiquitination is detected in the sample transfected with
both HA-K63Ub and Flag-LMP1 (Fig. 2A, lane 2). These
results indicate that LMP1 activates TRAF6 and results in
its auto-ubiquitination and are consistent with a previous
report (50). This is not surprising, since LMP1 is able to
engage TRAF6 (47) and therefore facilitates TRAF6 dimer-
ization or oligomerization.
Figure 2B shows that some TRAF6 and IRF7 proteins be-
come associated physically when coexpressed with K63onlyUb
(Fig. 2B, lane 3), and the association was enhanced in the
presence of LMP1 (Fig. 2B, lane 4). Without exogenously
expressed K63onlyUb, association between TRAF6 and IRF7
is also detectable but much weaker, despite the existence of
LMP1 (Fig. 2B, lanes 5 and 6). These data (Fig. 2B) indicate
that association of TRAF6 and IRF7 is mediated by LMP1-
stimulated ubiquitination.
TRAF6–Ubc-13-mediated ubiquitination is required for
IRF7 activation by LMP1. To check if TRAF6 is responsible
for LMP1-mediated ubiquitination of IRF7, we used a
TRAF6/ MEF cell line. IP with denatured proteins shows
that ubiquitinated IRF7 is detected in TRAF6/ cells in the
absence of LMP1 and greatly increased in its presence; ubiq-
uitination of IRF7 was not detected in TRAF6/ cells even in
the presence of LMP1 under our experimental conditions
(Fig. 3A).
We also reconstituted TRAF6/ MEFs with TRAF6 or
TRAF6(C70A), a mutant that has lost ligase activity, and
checked the ubiquitination of IRF7 by LMP1 in these cells. In
TRAF6/ MEFs reconstituted with TRAF6(C70A), IRF7
ubiquitination could not be detected even in the presence of
LMP1. However, in TRAF6/ MEFs reconstituted with
TRAF6, LMP1 is able to stimulate IRF7 ubiquitination
(Fig. 3B).
FIG. 3. TRAF6-Ubc13-mediated, LMP1-stimulated ubiquitination and transcriptional activity of IRF7. (A and B) TRAF6/ and TRAF6/
MEFs (5  106) were transfected with 2 g Flag-IRF7, 1 g LMP1, 1.5 g HA-K63Ub, and 0.5 g TRAF6 or TRAF6(C70A). Forty-eight hours
later, cells were collected for IP with denatured lysates. (A) LMP1 did not stimulate ubiquitination of IRF7 in TRAF6/ cells. IB, immuno-
blotting; WB, Western blotting; Flag, anti-Flag. (B) Ubiquitination of IRF7 in response to LMP1 is recovered in TRAF6/ MEFs reconstituted
with TRAF6 but not TRAF6(C70A). (C) Ubc13 siRNA decreases LMP1-promoted IRF7 activity. 293 cells in 12-well plates were transfected with
Ubc13 siRNA with the use of Lipofectamine reagent, following the manufacturer’s instructions. After 12 h, cells were transfected with 50 ng IRF7,
50 ng LMP1 or its mutants, 30 ng IFN-4p–Luc, and 20 ng Renilla. Twelve hours later, cells were transfected with the siRNA oligonucleotides again
and cultured for an additional 12 h before luciferase assays. The value for the vector control in control siRNA (siControl)-transfected cells was
set to 1. (D) Endogenous Ubc13 level is reduced by expression of Ubc13 siRNA in 293 cells.
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Ubc13 and Uev1A (or the functionally equivalent MMS2)
form an E2-conjugating enzyme complex named TRAF6-reg-
ulated IKK activator 1, which functions with certain E3 Ub
ligases, such as TRAF2 (49), TRAF6 (14), or RAD5 (56), to
catalyze K63-linked polyubiquitination. Expression of endoge-
nous Ubc13 (Fig. 3D) in 293 cells was reduced by RNA inter-
ference. The cells were then transfected with IRF7 and LMP1
plus Ub expression vectors. Luciferase results show that IRF7
activity stimulated by LMP1 is dramatically reduced in Ubc13
siRNA-transfected cells (Fig. 3C) as well as in small interfering
TRAF6-transfected cells (data not shown). Presumably,
TRAF6-mediated ubiquitination is abrogated by reducing the
expression of Ubc13 (14).
Together, these results indicate that LMP1 stimulates K63-
linked ubiquitination and transcriptional activity of IRF7
through TRAF6-Ubc13. Ubc13 is also involved in LMP1 acti-
vation of NFB since a dominant-negative form of Ubc13
inhibits LMP1 activation of NFB (40).
FIG. 4. Expression of shTRAF6 in Raji cells decreases endogenous ubiquitination and activity of IRF7. Raji cells with EBV type III latency
were infected with shTRAF6 retrovirus. After selection for 2 weeks, cells were collected for IP or transfected with 2 g IFN-4p–Luc and 1 g
Renilla constructs for a luciferase assay, performed 24 h later. (A) Endogenous IRF7 activity is decreased in shTRAF6-expressing cells.
(B) Endogenous ubiquitination of IRF7 is decreased in shTRAF6-expressing cells. IB, immunoblotting; IRF7, anti-IRF7. (C) Endogenous
TRAF6 level is reduced in shTRAF6-expressing cells.
FIG. 5. IRF7 is a substrate for TRAF6 E3 ligase and identification of IRF7 lysine sites for ubiquitination. (A) IRF7 is a substrate for TRAF6
E3 ligase. His-TRAF6 and His-TRAF6(C70A) proteins were expressed in and purified from E. coli, and Flag-IRF7 protein was expressed in and
purified from 293T cells. An in vitro ubiquitination assay was performed. After the reaction, solutions were heated in 1% SDS at 95°C to dissociate
protein interactions before IP with Flag antibody. Western blotting (WB) was performed with the antibodies indicated. IB, immunoblotting; Flag,
anti-Flag. (B) Identification of IRF7 ubiquitination sites. GST-IRF7-Flag and GST-TRAF6 were purified from E. coli. An in vitro ubiquitination
assay was performed (see details in Materials and Methods). Samples were separated on SDS gels and immunoblotted with Ub antibody. Blots
were stripped for reprobing IRF7 with Flag antibody. WT, wild type.
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Endogenous IRF7 ubiquitination and activity are reduced in
Raji cells stably expressing the shTRAF6 construct. Further,
to confirm the requirement of TRAF6 for LMP1-stimulated
ubiquitination and transcriptional activity of IRF7 in an en-
dogenous system, we knocked down expression of TRAF6 in
Raji cells by expressing an shTRAF6 construct. Raji cells are B
lymphocytes with an EBV type III latency phenotype and have
high levels of endogenous IRF7 and LMP1, and IRF7 in these
cells is highly ubiquitinated (27). As expected, when expression
of TRAF6 is reduced by shTRAF6 (Fig. 4C), endogenous
IRF7 transcriptional activity is reduced up to 70% (Fig. 4A).
Correspondingly, ubiquitination is also significantly reduced
(Fig. 4B). These results from a complete endogenous system
confirm that TRAF6 is responsible for LMP1-stimulated ubiq-
uitination and transcriptional activity of IRF7.
IRF7 is a substrate for TRAF6 E3 ligase. To eliminate the
possibility that the ubiquitination was mediated by a Ub ligase
activity other than TRAF6, we expressed and purified TRAF6
from bacteria, which lacks a Ub system (33). To eliminate the
possibility that IRF7 was coprecipitated with other proteins
from 293T cells, cell lysates were denatured before IP to dis-
sociate any noncovalently bound proteins (59).
As shown in Fig. 5A, ubiquitinated IRF7 is detected only in
the presence of the components His-TRAF6, Ubc13-UeV1a,
and K63-Ub, not in the absence of any of these components.
We also used a TRAF6 mutant, His-TRAF6(C70A), in which
cysteine 70, a key residue in the RING finger for TRAF6 E3
ligase activity (14), is mutated to alanine. Replacement of
His-TRAF6 with His-TRAF6(C70A) did not produce detect-
able ubiquitination of IRF7. The results demonstrate that
TRAF6 and its E3 ligase activity are required for IRF7 ubiq-
uitination and that IRF7 is a substrate for TRAF6 E3 ligase.
Lysines 444, 446, and 452 are critical for IRF7 activation.
Human IRF7 variant A has 15 lysine sites in total. To identify
IRF7 ubiquitination sites, we made a panel of deletion mutants
and lysine-to-arginine (K3R) point mutants and expressed
and purified the mutant proteins from E. coli to test their
abilities to be ubiquitinated by TRAF6 in vitro. As expected,
wild-type IRF7 protein is ubiquitinated in the presence of
TRAF6. Also, two deletion mutants, IRF7(1-370) and IRF7(1-
442), in which amino acids 371 to 503 and 443 to 503 are
deleted, respectively, are ubiquitinated, indicating that IRF7 is
ubiquitinated on multiple sites by TRAF6. The increased ubiq-
uitination of the deletion mutants may be explained by the fact
that deletion mutants are often assembled into a different or
misfolded conformation, leading to increased ubiquitination.
Although the decrease of ubiquitination of the single mutants
K444R, K446R, and K452R is not significant, due to the fact
FIG. 6. IRF7 lysines 444, 446, and 452 are functional ubiquitination sites. (A) Identification of IRF7 ubiquitination sites in vivo (see details in
Materials and Methods). WT, wild type; IB, immunoblotting; HC, heavy chain. (B and C) Lysines 444, 446, and 452 are responsible for IRF7
transactivation ability. (B) 293 cells in 24-well plates were transfected with 125 ng IRF7 or its K3R mutants, 25 ng IFN-4–Luc, and 10 ng Renilla
plasmids. IRF7, anti-IRF7; WT, wild type. Luciferase assays were performed 24 h after transfection. (C) 293 cells in six-well plates were
transfected with 0.5 g IRF7 or its ubiquitination-deficient mutants or the phosphorylation-deficient mutant IRF7(1-470). Forty-eight hours after
transfection, RNA was extracted and RT-PCR performed for detection of ISG56, IRF7, and actin mRNA.
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that multiple sites are ubiquitinated, the triple mutant with
lysines 444, 446, and 452 mutated to arginine (K444/446/452R)
has consistently displayed significant reduction in ubiquitina-
tion intensity (Fig. 5B).
We also performed in vivo ubiquitination assays with these
mutants, and similar results were obtained (Fig. 6A). Thus,
both in vitro and in vivo ubiquitination assays indicate that
IRF7 is ubiquitinated by TRAF6 on multiple lysine sites and
suggest that K444, K446, and K452 may be TRAF6-targeted
ubiquitination sites. To test if these ubiquitination-deficient
mutants are defective in transactivation ability, we first per-
formed luciferase assays. As seen in Fig. 6B, wild-type IRF7
strongly transactivates the IFN-4 promoter, and IRF with
lysines 373 and 375 mutated to arginine [IRF7(K373/375R)]
transactivates it as well. Strikingly, single or double ubiquitin-
ation-deficient mutations of K444, K446, or K452 dramati-
cally reduce the ability to transactivate the IFN-4 promoter.
Consistently, IRF7(K444R) has the highest reduction and
IRF7(K446R) has the lowest reduction of transcriptional ac-
tivity. Impressively, the triple mutant IRF7(K444/446/452R)
completely loses its ability to transactivate the promoter. We
also tested the abilities of the IRF7 mutants to transactivate an
endogenous IRF7 target gene by measuring ISG56 mRNA
with quantitative RT-PCR. Parallel results were obtained (Fig.
6C). Wild-type IRF7 and IRF7(K373/375R) stimulate ISG56
mRNA levels substantially, but other tested ubiquitination-
deficient mutants did not. IRF7(K444/446/452R) and the phos-
phorylation-deficient mutant IRF7(1-470), which lacks all C-
terminal functional phosphorylation sites, stimulated ISG56
mRNA levels only to control levels (Fig. 6C). Thus, these three
of five total lysines tested are functional ubiquitination sites on
IRF7; mutation of all these three sites reduces ubiquitination
of IRF7 and, correspondingly, its transactivational ability.
To confirm these observations, we tested if these ubiquitin-
ation-deficient mutants have reduced abilities to be activated
by LMP1. As expected, wild-type IRF7 and IRF7(K373/375R)
are similarly strongly activated by LMP1. However, IRF7
(K444R), IRF7(K446R), and IRF7(K452R) all have significantly
decreased activities compared to those of wild-type IRF7 and
IRF7(K373/375R). Again, the triple mutant IRF7(K444/446/
452R) completely loses the ability to respond to LMP1 stimula-
tion (Fig. 7A). Further, we studied the activities of these mutants
in response to the IRF7 kinase IKKε (48). The results were
similar to those obtained with LMP1 (Fig. 7B).
FIG. 7. Transactivation response of IRF7 ubiquitination-deficient mutants to LMP1 and to IKKε. (A, B, and C) 293 cells in 24-well plates were
transfected with 25 ng (A) or 50 ng (B and C) of IRF7 or its K3R mutants, 25 ng LMP1 or 100 ng IKKε or the vector control, 25 ng IFN-4–Luc,
and 10 ng Renilla. Luciferase assays were performed 24 h after transfection. (A) IRF7 functional ubiquitination sites are required for its activation
in response to LMP1 (solid bars). The expression levels of IRF7, IRF7(K373/375R), and IRF7(K444/446/452R) are shown at the bottom. WT, wild
type; IRF7, anti-IRF7. (B) IRF7 functional ubiquitination sites are required for its activation in response to IKKε (solid bars). (C) The IRF7
ubiquitination-deficient mutant IRF7(K444/446/452R) does not respond to LMP1 and Ub.
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Together, these results show that lysines 444, 446, and 452,
but not K373 and K375, are key ubiquitination sites that are
responsible for IRF7 activation. More importantly, since these
ubiquitination-deficient mutants have little or dramatically re-
duced transactivation ability in response to IKKε as well as to
LMP1, ubiquitination on these sites seems to be a prelude to
IRF7 phosphorylation rather than simply enhancing its tran-
scriptional activity.
Ubiquitination of IRF7 is independent of its functional
phosphorylation sites. K48-linked ubiquitination is usually
preceded by phosphorylation (26). To check whether K63-
linked ubiquitination of IRF7 is dependent on the two major
phosphorylation sites Ser 477/479, we checked the ubiquitin-
ation abilities of IRF7, IRF7(S477D/S479D) [designated
IRF7(2D)], IRF7(S477A/S479A) [designated IRF7(2A)]
(which has the two major phosphorylation sites Ser 477/479
mutated to alanines [37]), and IRF7(1-470) in response to
LMP1 with “denatured” IP. Wild-type IRF7, as well as the two
phosphorylation-deficient mutants IRF7(2A) and IRF7(1-
470), are all ubiquitinated in the presence of LMP1 and
K63onlyUb, and the phosphorylation-deficient mutants may
have even stronger capacity for ubiquitination. However, ubiq-
uitination of IRF7(2D) is not detectable under our experimen-
tal conditions (Fig. 8A). To assess this in a relatively endoge-
nous system, we made 293 cells stably expressing Flag-tagged
versions of these constructs. LMP1 and Ub expression plas-
mids were transfected in these stable cell lines. Similar results
were observed (Fig. 8B). These data indicate that LMP1 can
stimulate ubiquitination of IRF7 independently of its C-termi-
nal functional phosphorylation sites and suggest that phos-
phorylation may negatively regulate K63-linked ubiquitination.
DISCUSSION
The principal findings in this study are the unequivocal iden-
tification of IRF7 as a substrate for TRAF6 E3 ligase and the
first identification of ubiquitination sites on IRF7 that mediate
its activation. In addition, we present preliminary evidence that
such ubiquitination is independent of C-terminal major func-
tional phosphorylation sites. These findings have broader sig-
nificance for IRF7-mediated innate immunity in addition to
LMP1 signaling leading to IRF7 activation.
We have recently shown that regulatory ubiquitination plays
a central role in activation of IRF7 by LMP1 (27). TRAF6 has
long been known to be associated with intracellular signaling
by LMP1, but its role has remained obscure (40, 47, 57, 62).
Here, we show for the first time that IRF7 is a substrate for
TRAF6 E3 ligase in vitro as well as in vivo. This finding sup-
plies a key missing link between LMP1 and IRF7. Most im-
portant, we identify that Lys 444, 446, and 452 are functional
ubiquitination sites required for IRF7 activation, which pro-
vides the first line of support for our hypothesis that regulatory
ubiquitination of IRF7 is a prelude to its phosphorylation. In
addition, we show that, in contrast to K48-linked ubiquitina-
tion, which is usually preceded by phosphorylation, K63-linked
ubiquitination of IRF7 operates independently of its C-termi-
nal major functional phosphorylation sites.
Ubiquitination has been implicated in TLR signaling leading
to IRF7 activation (30). It is likely that this activation is direct.
However, it is also possible that as-yet-unidentified targets,
which may be involved in activation of an IRF7 kinase, such as
IL-1 receptor-associated kinase 1, IKK, or the noncanonical
IKK TANK-binding kinase 1 or IKKε (23), are activated
through ubiquitination (10) (Fig. 9). In our previous study, we
showed that IRF7 can be ubiquitinated directly through
K63-Ub chains, resulting in IRF7 activation (27), suggesting
that IRF7 can be activated directly by its own ubiquitination or
by ubiquitination-mediated phosphorylation (Fig. 9). Here, we
identify three key lysine sites which are required for IRF7
activation. Mutation of these sites results in consistent de-
creases in ubiquitination intensity and also abrogates the trans-
activation ability of IRF7. Thus, our results with these ubiq-
uitination-deficient mutants imply that ubiquitination of IRF7
precedes its phosphorylation (Fig. 9), in contrast to what was
found for K48-linked ubiquitination-mediated degradation,
which is usually preceded by phosphorylation (reviewed in
FIG. 8. Ubiquitination of IRF7 is independent of its C-terminal functional phosphorylation sites. (A) 293 cells in 60-mm dishes were transfected
with 0.5 g Flag-IRF7 or its mutants, together with 0.2 g LMP1 and 0.5 g HA-K63onlyUb. Cells were collected 48 h after transfection for
“denatured” IP with anti-Flag (Flag) and blotting with anti-HA or anti-Flag antibodies. IB, immunoblotting. (B) 293 cells stably expressing the
indicated proteins in 60-mm dishes were transfected with 0.2 g LMP1 and 0.5 g HA-K63Ub expression plasmids. Cells were collected 48 h after
transfection, and IP was performed with denatured lysates with anti-Flag and blotting with anti-HA or anti-Flag antibodies.
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references 19 and 26). In fact, preliminary data from immuno-
fluorescence staining show that IRF7(K444/446/452R) did not
translocate to the nucleus in response to LMP1 (S. Ning and
J. S. Pagano, unpublished data). In addition, a kinase may be
activated directly and regulated by ubiquitination (Fig. 9). In
support of this possibility, the activity of IKK	, a kinase in the
NFB pathways, has been shown to be regulated by mono-
ubiquitination (9).
Direct identification of ubiquitination sites by mass spec-
trometry remains technically challenging, especially for higher
eukaryotes where knock-in mutation is not nearly as feasible as
in yeast cells. However, ubiquitination assays with K3R mu-
tation have been extensively used for identification of ubiquitin-
ation lysine sites despite the limitations of the assay (1, 18, 25,
33, 38, 45, 68). Our studies showing that the triple mutant
IRF7(K444/446/452R) significantly lost ubiquitination were
carried out in the context of the full-length IRF7 protein and,
together with the correlative functional analyses, meet if not
exceed current standards for mapping ubiquitination sites.
In addition to ubiquitination, many other posttranslational
modifications can occur on lysine sites, such as sumoylation,
ISGylation, NEDDylation, and acetylation (15, 32). Since our
ubiquitination assays (Fig. 5B and 6A), together with other
data reported here (Fig. 7C), show that these mutants exhibit
consistent decreases in ubiquitination intensity and that Ub
significantly increases the activity of IRF7, but not that of
IRF7(K444/446/452R), stimulated by LMP1, we reason that
ubiquitination is at least one of the modifications that contrib-
ute to IRF7 activation.
Our data show that TRAF6 is critical for LMP1-stimulated
IRF7 transcriptional activity. TRAF6 is also required for
MyD88-dependent/TRIF-independent TLR7/9 signaling lead-
ing to production of IFN-Is (30, 44). However, TRAF6 is
dispensable for IFN-	 production by TRIF-dependent/
MyD88-independent TLR4 signaling, for which TRAF3 is re-
quired instead (20). Similar to TRAF6, TRAF3 is also an E3
ligase (31). However, unlike TRAF6, which is engaged only in
MyD88-dependent TLR pathways, TRAF3 is also engaged in
TRIF-dependent TLR pathways, in addition to MyD88-depen-
dent pathways (31). Whether TRAF3 alternatively targets
IRF7 on these same sites for ubiquitination is an interesting
question.
Besides the three lysine sites required for IRF7 activation,
our results show that IRF7 is ubiquitinated by TRAF6 on
FIG. 9. Signaling from LMP1 and TLR to IRF7 activation. Shown is a scheme of the signaling cascade from LMP1 or TLR to activation of
IRF7. LMP1 recruits TRAF6 through TRAF2. The latter protein may act as an E3 ligase for K63-linked ubiquitination of RIP1, which is required
for downstream ubiquitination of IRF7 by TRAF6. TLR7/9 recruits TRAF6 through the adaptor protein MyD88. Although RIP1 is not required
for TLR3/4 signaling for activation of IRF3 (13), it may be involved in TLR3 signaling leading to IRF7 activation (Michelle Kelliher, personal
communication). After recruitment, TRAF6 is auto-ubiquitinated and activated upon dimerization or oligomerization. Then, TRAF6 ubiquitinates
and activates IRF7 through K63-Ub chains (pathway 1), which may recruit an IRF7 kinase (IKK, IKKε, TANK-binding kinase 1, or IL-1
receptor-associated kinase 1) for IRF7 phosphorylation. And TRAF6-mediated ubiquitination may also regulate the activity of an IRF7 kinase
(pathway 2). Solid arrows indicate regulatory pathways identified, and dashed arrows indicate pathways which are proposed but still under study.
P, phosphorylated.
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multiple sites, some of which are located in amino acids 1 to
370 (Fig. 5B). We will profile all the ubiquitination sites and
study whether selection of ubiquitination sites is linked to
differential functions. Regulatory ubiquitination of a specific
site(s) may stabilize IRF7 protein, which has a short half-life
and has low levels in normal cells due to degradation by the
proteasome-dependent pathway (65). K63-linked ubiquitina-
tion is well known to stabilize proteins. For example, K63-
linked Ub chains stabilize RIP through binding to NEMO that
results in impairment of the interaction between RIP and A20
(60); the latter targets RIP for degradation (59). LMP1 has
also been reported to stabilize the oncoprotein MDM2
through ubiquitination (36). In cells with EBV type III latency,
IRF7 levels are high in the presence of LMP1. One reason is
that LMP1 induces expression of IRF7 (67), but another, po-
tentially better reason is proposed here, that is, LMP1-stimu-
lated, K63-linked ubiquitination protects IRF7 from degrada-
tion. Similarly, after virus infection, the level of IRF7 increases
dramatically, which is due in part to induction by IFN pro-
duced upon virus infection and also, possibly more impor-
tantly, to ubiquitination-mediated stabilization. In addition,
ubiquitination is known to promote DNA binding of transcrip-
tion factors and facilitate the assembly of protein complexes
(reviewed in references 3, 15, 32, 42, and 52).
We believe that K63-linked ubiquitination of IRF7 is likely
to be a ubiquitous mechanism triggered by a variety of infec-
tions. The ubiquitination phenomena reported here and earlier
(27), which are set into motion early in the LMP1 signaling
mechanism, are likely to be paralleled in signaling initiated by
other TNFR members, especially TNFR and CD40, and for
targets other than IRF7.
ACKNOWLEDGMENTS
We are grateful to Tak Mak for providing TRAF6/ and / MEFs
and Arnd Kieser, David Boone, Averil Ma, Nancy Raab-Traub, Rong-
tuan Lin, and John Hiscott, who were generous in providing plasmids
for this research. We thank Jenny Ting and Yue Xiong for careful
reading of and helpful suggestions on the manuscript. We also appre-
ciate helpful input from Leslie Huye.
This work was supported by a grant from the NIH (R21-AI042371).
REFERENCES
1. Abbott, D. W., A. Wilkins, J. M. Asara, and L. C. Cantley. 2004. The Crohn’s
disease protein, NOD2, requires RIP2 in order to induce ubiquitinylation of
a novel site on NEMO. Curr. Biol. 14:2217–2227.
2. Baccala, R., K. Hoebe, D. H. Kono, B. Beutler, and A. N. Theofilopoulos.
2007. TLR-dependent and TLR-independent pathways of type I interferon
induction in systemic autoimmunity. Nat. Med. 13:543–551.
3. Ben-Neriah, Y. 2002. Regulatory functions of ubiquitination in the immune
system. Nat. Immunol. 3:20–26.
4. Besse, A., B. Lamothe, A. D. Campos, W. K. Webster, U. Maddineni, S. C.
Lin, H. Wu, and B. G. Darnay. 2007. TAK1-dependent signaling requires
functional interaction with TAB2/TAB3. J. Biol. Chem. 282:3918–3928.
5. Boone, D. L., E. E. Turer, E. G. Lee, R. C. Ahmad, M. T. Wheeler, C. Tsui,
P. Hurley, M. Chien, S. Chai, O. Hitotsumatsu, E. McNally, C. Pickart, and
A. Ma. 2004. The ubiquitin-modifying enzyme A20 is required for termina-
tion of Toll-like receptor responses. Nat. Immunol. 5:1052–1060.
6. Bouwmeester, T., A. Bauch, H. Ruffner, P. O. Angrand, G. Bergamini, K.
Croughton, C. Cruciat, D. Eberhard, J. Gagneur, S. Ghidelli, C. Hopf, B.
Huhse, R. Mangano, A. M. Michon, M. Schirle, J. Schlegl, M. Schwab, M. A.
Stein, A. Bauer, G. Casari, G. Drewes, A. C. Gavin, D. B. Jackson, G.
Joberty, G. Neubauer, J. Rick, B. Kuster, and G. Superti-Furga. 2004. A
physical and functional map of the human TNF-/NF-B signal transduction
pathway. Nat. Cell Biol. 6:97–105.
7. Bradley, J., and J. S. Pober. 2001. Tumor necrosis factor receptor-associated
factors (TRAFs). Oncogene 20:6482–6491.
8. Brinkmann, M. M., and T. F. Schulz. 2006. Regulation of intracellular
signalling by the terminal membrane proteins of members of the Gamma-
herpesvirinae. J. Gen. Virol. 87:1047–1074.
9. Carter, R. S., K. N. Pennington, P. Arrate, E. M. Oltz, and D. W. Ballard.
2005. Site-specific monoubiquitination of IB kinase IKK	 regulates its
phosphorylation and persistent activation. J. Biol. Chem. 280:43272–43279.
10. Chen, Z. J. 2005. Ubiquitin signalling in the NF-B pathway. Nat. Cell Biol.
7:758–765.
11. Chung, J. Y., Y. C. Park, H. Ye, and H. Wu. 2002. All TRAFs are not created
equal: common and distinct molecular mechanisms of TRAF-mediated sig-
nal transduction. J. Cell Sci. 115:679–688.
12. Colonna, M. 2007. TLR pathways and IFN-regulatory factors: to each its
own. Eur. J. Immunol. 37:306–309.
13. Cusson-Hermance, N., S. Khurana, T. H. Lee, K. A. Fitzgerald, and M. A.
Kelliher. 2005. Rip1 mediates the Trif-dependent Toll-like receptor 3- and
4-induced NF-B activation but does not contribute to interferon regulatory
factor 3 activation. J. Biol. Chem. 280:36560–36566.
14. Deng, L., C. Wang, E. Spencer, L. Yang, A. Braun, J. You, C. Slaughter, C.
Pickart, and Z. J. Chen. 2000. Activation of the IB kinase complex by
TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a
unique polyubiquitin chain. Cell 103:351–361.
15. Dye, B. T., and B. A. Schulman. 2007. Structural mechanisms underlying
posttranslational modification by ubiquitin-like proteins. Annu. Rev. Bio-
phys. Biomol. Struct. 36:131–150.
16. Eliopoulos, A. G., and L. S. Young. 2001. LMP1 structure and signal trans-
duction. Semin. Cancer Biol. 11:435–444.
17. Farina, A., F. Faiola, and E. Martinez. 2004. Reconstitution of an E box-
binding Myc:Max complex with recombinant full-length proteins expressed
in Escherichia coli. Protein Expr. Purif. 34:215–222.
18. Gack, M. U., Y. C. Shin, C. H. Joo, T. Urano, C. Liang, L. Sun, O. Takeuchi,
S. Akira, Z. Chen, S. Inoue, and J. U. Jung. 2007. TRIM25 RING-finger E3
ubiquitin ligase is essential for RIG-I-mediated antiviral activity. Nature
446:916–920.
19. Glickman, M. H., and A. Ciechanover. 2002. The ubiquitin-proteasome pro-
teolytic pathway: destruction for the sake of construction. Physiol. Rev.
82:373–428.
20. Hacker, H., V. Redecke, B. Blagoev, I. Kratchmarova, L. C. Hsu, G. G. Wang,
M. P. Kamps, E. Raz, H. Wagner, G. Hacker, M. Mann, and M. Karin. 2006.
Specificity in Toll-like receptor signalling through distinct effector functions
of TRAF3 and TRAF6. Nature 439:204–207.
21. Hiscott, J. 2007. Convergence of the NF-B and IRF pathways in the reg-
ulation of the innate antiviral response. Cytokine Growth Factor Rev. 18:
483–490.
22. Hoebe, K., and B. Beutler. 2006. TRAF3: a new component of the TLR-
signaling apparatus. Trends Mol. Med. 12:187–189.
23. Honda, K., and T. Taniguchi. 2006. IRFs: master regulators of signalling by
Toll-like receptors and cytosolic pattern-recognition receptors. Nat. Rev.
Immunol. 6:644–658.
24. Honda, K., H. Yanai, H. Negishi, M. Asagiri, M. Sato, T. Mizutani, N.
Shimada, Y. Ohba, A. Takaoka, N. Yoshida, and T. Taniguchi. 2005. IRF-7
is the master regulator of type-I interferon-dependent immune responses.
Nature 434:772–777.
25. Huang, T. T., S. M. Wuerzberger-Davis, Z. H. Wu, and S. Miyamoto. 2003.
Sequential modification of NEMO/IKK
 by SUMO-1 and ubiquitin medi-
ates NF-B activation by genotoxic stress. Cell 115:565–576.
26. Hunter, T. 2007. The age of crosstalk: phosphorylation, ubiquitination, and
beyond. Mol. Cell 28:730–738.
27. Huye, L. E., S. B. Ning, M. Kelliher, and J. S. Pagano. 2007. Interferon
regulatory factor 7 is activated by a viral oncoprotein through RIP-depen-
dent ubiquitination. Mol. Cell. Biol. 27:2910–2918.
28. Iwasaki, A., and R. Medzhitov. 2004. Toll-like receptor control of the adap-
tive immune responses. Nat. Immunol. 5:987–995.
29. Kawai, T., and S. Akira. 2007. TLR signaling. Semin. Immunol. 19:24–32.
30. Kawai, T., S. Sato, K. J. Ishii, C. Coban, H. Hemmi, M. Yamamoto, K. Terai,
M. Matsuda, J. I. Inoue, S. Uematsu, O. Takeuchi, and S. Akira. 2004.
Interferon  induction through Toll-like receptors involves a direct interac-
tion of IRF7 with MyD88 and TRAF6. Nat. Immunol. 5:1061–1068.
31. Kayagaki, N., Q. Phung, S. Chan, R. Chaudhari, C. Quan, K. M. O’Rourke,
M. Eby, E. Pietras, G. Cheng, J. F. Bazan, Z. Zhang, D. Arnott, and V. M.
Dixit. 2007. DUBA: a deubiquitinase that regulates type I interferon pro-
duction. Science 318:1628–1632.
32. Kerscher, O., R. Felberbaum, and M. Hochstrasser. 2006. Modification of
proteins by ubiquitin and ubiquitin-like proteins. Annu. Rev. Cell Dev. Biol.
22:159–180.
33. Lamothe, B., A. Besse, A. D. Campos, W. K. Webster, H. Wu, and B. G.
Darnay. 2007. Site-specific Lys-63-linked tumor necrosis factor receptor-
associated factor 6 auto-ubiquitination is a critical determinant of IB kinase
activation. J. Biol. Chem. 282:4102–4112.
34. Lamothe, B., W. K. Webster, A. Gopinathan, A. Besse, A. D. Campos, and
B. G. Darnay. 2007. TRAF6 ubiquitin ligase is essential for RANKL signal-
ing and osteoclast differentiation. Biochem. Biophys. Res. Commun. 359:
1044–1049.
35. Li, H. P., and Y. S. Chang. 2003. Epstein-Barr virus latent membrane protein
1: structure and functions. J. Biomed. Sci. 10:490–504.
36. Li, L., Z. Li, S. Zhou, L. Xiao, L. Guo, Y. Tao, M. Tang, Y. Shi, W. Li, W. Yi,
VOL. 28, 2008 IRF7 IS ACTIVATED VIA TRAF6-MEDIATED UBIQUITINATION 6545
and Y. Cao. 2007. Ubiquitination of MDM2 modulated by Epstein-Barr virus
encoded latent membrane protein 1. Virus Res. 130:275–280.
37. Lin, R., Y. Mamane, and J. Hiscott. 2000. Multiple regulatory domains
control IRF-7 activity in response to virus infection. J. Biol. Chem. 275:
34320–34327.
38. Lohrum, M. A. E., D. B. Woods, R. L. Ludwig, E. Balint, and K. H. Vousden.
2001. C-terminal ubiquitination of p53 contributes to nuclear export. Mol.
Cell. Biol. 21:8521–8532.
39. Lomaga, M. A., W. C. Yeh, I. Sarosi, G. S. Duncan, C. Furlonger, A. Ho, S.
Morony, C. Capparelli, G. Van, S. Kaufman, A. van der Heiden, A. Itie, A.
Wakeham, W. Khoo, T. Sasaki, Z. Cao, J. M. Penninger, C. J. Paige, D. L.
Lacey, C. R. Dunstan, W. J. Boyle, D. V. Goeddel, and T. W. Mak. 1999.
TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40,
and LPS signaling. Genes Dev. 13:1015–1024.
40. Luftig, M., E. Prinarakis, T. Yasui, T. Tsichritzis, E. Cahir-McFarland,
J. Inoue, H. Nakano, T. W. Mak, W. C. Yeh, X. Li, S. Akira, N. Suzuki, S.
Suzuki, G. Mosialos, and E. Kieff. 2003. Epstein-Barr virus latent membrane
protein 1 activation of NF-B through IRAK1 and TRAF6. Proc. Natl.
Acad. Sci. USA 100:15595–15600.
41. Miller, W. E., G. Mosialos, E. Kieff, and N. Raab-Traub. 1997. Epstein-Barr
virus LMP1 induction of the epidermal growth factor receptor is mediated
through a TRAF signaling pathway distinct from NF-B activation. J. Virol.
71:586–594.
42. Mukhopadhyay, D., and H. Riezman. 2007. Proteasome-independent func-
tions of ubiquitin in endocytosis and signaling. Science 315:201–205.
43. Nestle, F. O., C. Conrad, A. Tun-Kyi, B. Homey, M. Gombert, O. Boyman, G.
Burg, Y. J. Liu, and M. Gilliet. 2005. Plasmacytoid predendritic cells initiate
psoriasis through interferon- production. J. Exp. Med. 202:135–143.
44. Oganesyan, G., S. K. Saha, B. Guo, J. Q. He, A. Shahangian, B. Zarnegar,
A. Perry, and G. Cheng. 2006. Critical role of TRAF3 in the Toll-like
receptor-dependent and -independent antiviral response. Nature 439:208–
211.
45. Read, M. A., J. E. Brownell, T. B. Gladysheva, M. Hottelet, L. A. Parent,
M. B. Coggins, J. W. Pierce, V. N. Podust, R. S. Luo, V. Chau, and V. J.
Palombella. 2000. Nedd8 modification of Cul-1 activates SCF	TrCP-depen-
dent ubiquitination of IB. Mol. Cell. Biol. 20:2326–2333.
46. Sanz, L., M. T. az-Meco, H. Nakano, and J. Moscat. 2000. The atypical
PKC-interacting protein p62 channels NF-kappaB activation by the IL-1-
TRAF6 pathway. EMBO J. 19:1576–1586.
47. Schultheiss, U., S. Puschner, E. Kremmer, T. W. Mak, H. Engelmann, W.
Hammerschmidt, and A. Kieser. 2001. TRAF6 is a critical mediator of signal
transduction by the viral oncogene latent membrane protein 1. EMBO J.
20:5678–5691.
48. Sharma, S., B. R. tenOever, N. Grandvaux, G. P. Zhou, R. Lin, and J.
Hiscott. 2003. Triggering the interferon antiviral response through an IKK-
related pathway. Science 300:1148–1151.
49. Shi, C. S., and J. H. Kehrl. 2003. Tumor necrosis factor (TNF)-induced
germinal center kinase-related (GCKR) and stress-activated protein kinase
(SAPK) activation depends upon the E2/E3 complex Ubc13-Uev1A/TNF
receptor-associated factor 2 (TRAF2). J. Biol. Chem. 278:15429–15434.
50. Song, Y. J., K. Y. Jen, V. Soni, E. Kieff, and E. Cahir-McFarland. 2006. IL-1
receptor-associated kinase 1 is critical for latent membrane protein 1-in-
duced p65/RelA serine 536 phosphorylation and NF-B activation. Proc.
Natl. Acad. Sci. USA 103:2689–2694.
51. Soni, V., E. Cahir-McFarland, and E. Kieff. 2007. LMP1 TRAFficking acti-
vates growth and survival pathways. Adv. Exp. Med. Biol. 597:173–187.
52. Sun, L., and Z. J. Chen. 2004. The novel functions of ubiquitination in
signaling. Curr. Opin. Cell Biol. 16:119–126.
53. Takaoka, A., T. Tamura, and T. Taniguchi. 2008. Interferon regulatory
factor family of transcription factors and regulation of oncogenesis. Cancer
Sci. 99:467–478.
54. Tamura, T., H. Yanai, D. Savitsky, and T. Taniguchi. 2008. The IRF family
transcription factors in immunity and oncogenesis. Annu. Rev. Immunol.
26:535–584.
55. Uematsu, S., and S. Akira. 2007. Toll-like receptors and type I interferons.
J. Biol. Chem. 282:15319–15323.
56. Ulrich, H. D., and S. Jentsch. 2000. Two RING finger proteins mediate
cooperation between ubiquitin-conjugating enzymes in DNA repair. EMBO
J. 19:3388–3397.
57. Wan, J., L. Sun, J. W. Mendoza, Y. L. Chui, D. P. Huang, Z. J. Chen, N.
Suzuki, S. Suzuki, W. C. Yeh, S. Akira, K. Matsumoto, Z. G. Liu, and Z. Wu.
2004. Elucidation of the c-Jun N-terminal kinase pathway mediated by Ep-
stein-Barr virus-encoded latent membrane protein 1. Mol. Cell. Biol. 24:192–
199.
58. Wang, C., L. Deng, M. Hong, G. R. Akkaraju, J. Inoue, and Z. J. Chen. 2001.
TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature 412:346–
351.
59. Wertz, I. E., K. M. O’Rourke, H. Zhou, M. Eby, L. Aravind, S. Seshagiri, P.
Wu, C. Wiesmann, R. Baker, D. L. Boone, A. Ma, E. V. Koonin, and V. M.
Dixit. 2004. De-ubiquitination and ubiquitin ligase domains of A20 down-
regulate NF-kappaB signalling. Nature 430:694–699.
60. Wu, C. J., D. B. Conze, T. Li, S. M. Srinivasula, and J. D. Ashwell. 2006.
Sensing of Lys 63-linked polyubiquitination by NEMO is a key event in
NF-B activation. Nat. Cell Biol. 8:398–406.
61. Wu, H., and J. R. Arron. 2003. TRAF6, a molecular bridge spanning adaptive
immunity, innate immunity and osteoimmunology. Bioessays 25:1096–1105.
62. Wu, L., H. Nakano, and Z. Wu. 2006. The C-terminal activating region 2 of
the Epstein-Barr virus-encoded latent membrane protein 1 activates NF-B
through TRAF6 and TAK1. J. Biol. Chem. 281:2162–2169.
63. Yoneyama, M., and T. Fujita. 2007. RIG-I family RNA helicases: cytoplas-
mic sensor for antiviral innate immunity. Cytokine Growth Factor Rev.
18:545–551.
64. Yoneyama, M., and T. Fujita. 2007. Function of RIG-I-like receptors in
antiviral innate immunity. J. Biol. Chem. 282:15315–15318.
65. Yu, Y., S. E. Wang, and G. S. Hayward. 2005. The KSHV immediate-early
transcription factor RTA encodes ubiquitin E3 ligase activity that targets
IRF7 for proteosome-mediated degradation. Immunity 22:59–70.
66. Zhang, L., and J. S. Pagano. 1997. IRF-7, a new interferon regulatory factor
associated with Epstein-Barr virus latency. Mol. Cell. Biol. 17:5748–5757.
67. Zhang, L., and J. S. Pagano. 2000. Interferon regulatory factor 7 is induced
by Epstein-Barr virus latent membrane protein 1. J. Virol. 74:1061–1068.
68. Zhou, H., I. Wertz, K. O’Rourke, M. Ultsch, S. Seshagiri, M. Eby, W. Xiao,
and V. M. Dixit. 2004. Bcl10 activates the NF-B pathway through ubiquitin-
ation of NEMO. Nature 427:167–171.
6546 NING ET AL. MOL. CELL. BIOL.
